Mandate

VINGE ADVISES DOMETIC IN RELATION TO ITS LISTING ON NASDAQ STOCKHOLM

November 25, 2015

Vinge advises Dometic Group AB (publ) in relation to its listing on Nasdaq Stockholm. A prospectus was published on 11 November 2015 and the first day of trading on Nasdaq Stockholm was 25 November 2015. The price in the offering was set at SEK 48 per share, corresponding to a market capitalisation of SEK 14,200 million for Dometic. The total value of the offering amounts to SEK 5,396 million, assuming that the over-allotment option is exercised in full.

Dometic provides branded solutions for mobile living in the areas of Climate, Hygiene & Sanitation and Food & Beverage. The Company manufactures and sells a broad range of products within these areas for use in recreational vehicles (such as motorhomes and caravans or towables), trucks and premium cars, pleasure and work boats, and for a variety of other uses. Products include air conditioners, furnaces, awnings, vents and windows & doors within Climate; water heaters and toilets within Hygiene & Sanitation; and refrigerators, cooking equipment, ovens and mobile coolers within Food & Beverage.

Vinge’s team primarily consisted of Jesper Schönbeck, Christina Kokko, Jo-Anna Nordström, David Andersson, Joakim Hagberg, Sabina Börjesson, Linda Sengul, Gustav Tengblad and Amanda Knutsson. Louise Brorsson Salomon and Adam Sandberg assisted in financing related matters, and Mattias Schömer, Tora Hansjons and Henrik Wastensson assisted in tax related matters.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026